Valchlor

Quick links to important sections

Valchlor

Selected form

Treatment option: Lymphoma, Mycosis Fungoides

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valchlor

Property Description
Active ingredient Chlormethine (Mechlorethamine)
Form Topical Gel Formulation
Pharmacological class Antineoplastic Agent (Alkylating Agent)
Route of administration Topical (Dermal)
Origin Synthetic

Valchlor is a specialized, prescription-only medication whose active ingredient is chlormethine, also known as mechlorethamine. This substance is a synthetic compound derived from the nitrogen mustard family, which defines its chemical origin. It belongs to the potent pharmacological class of antineoplastic agents, specifically recognized as an alkylating agent and cytotoxic agent. Pharmacological studies support the designation of chlormethine as a highly effective agent in managing specific cellular disorders.

Valchlor: A Specialized Topical Gel Formulation

Valchlor's dosage form is a topical gel formulation designed for direct application to the skin, representing a form of topical therapy. This form is a differentiating factor, as historical or alternative preparations of mechlorethamine have often involved systemic administration. The formulation contains the active substance, chlormethine, suspended within a gel base, allowing for localized dermal administration.

This approach contrasts fundamentally with systemic treatments, which circulate throughout the entire body. The benefit of using this unique topical gel is the ability to achieve a concentrated effect of the alkylating agent precisely at the site of abnormal cell growth, minimizing internal systemic exposure to the potent compound. This localized delivery is clinically recognized for providing a targeted therapeutic effect.

How Valchlor's Action Contributes to its Purpose

The primary action of chlormethine is cytotoxic, meaning it is capable of causing damage or destruction to certain targeted cells by acting as an alkylating agent. This mechanism involves the active ingredient chemically altering the genetic material, or DNA, within the abnormal cells. By inflicting this damage, Valchlor prevents these rapidly multiplying cells from successfully dividing and proliferating. This resulting inhibition of cell growth is the fundamental benefit that drives the medication's therapeutic purpose in managing conditions characterized by uncontrolled cell proliferation.

Regulatory References

  1. NCI Drug Dictionary: Mechlorethamine Hydrochloride

What side effects are possible with Valchlor?

Possible Side Effects and Safety Information

The safety profile of Valchlor (chlormethine gel) is established primarily through its topical application, with documented adverse events focusing mostly on the skin and accidental exposure risks, as defined by regulatory labeling.


Common Adverse Reactions

Official labeling classifies several localized, cutaneous reactions as the most common adverse reactions associated with the gel's use. These effects were observed frequently in clinical studies and are often related to the site of application.

  • Dermatitis: The most frequently reported reaction, often manifesting as redness, inflammation, blistering, or ulceration of the skin.
  • Pruritus (Itching).
  • Bacterial skin infection.
  • Skin ulceration or blistering.
  • Skin hyperpigmentation (darkening).

Serious Safety Considerations

Certain risks are highlighted in the official prescribing information due to their potential seriousness, often stemming from the drug's nature as an alkylating agent:

  • Exposure Injury: Accidental contact with the eyes or mucous membranes can result in severe, irreversible anterior eye injury and blindness, or severe mucosal ulceration.
  • Non-Melanoma Skin Cancer (NMSC): An increased risk of developing NMSC is a documented safety consideration during and after treatment.
  • Hypersensitivity: The medication is contraindicated in individuals with a known severe hypersensitivity to mechlorethamine, and anaphylaxis has been reported with topical formulations.

Population-Specific Notes

The safety information includes warnings related to specific groups:

  • Embryo-Fetal Harm: Based on its cytotoxic mechanism, Valchlor has the potential to cause fetal harm when used during pregnancy.
  • Geriatric Population: Patients aged 65 and above were observed to be more susceptible to experiencing cutaneous adverse reactions.

Overdose and Emergency Response

The regulatory overdose profile for Valchlor (chlormethamine topical gel) focuses on the acute toxicity that arises from unintended exposure to the cytotoxic agent. Due to its potent nature, overdose risks are categorized by contact with sensitive non-skin tissues and by accidental ingestion.

Accidental Local Exposure

Contact with the eyes or mucous membranes (such as the mouth or nose) may result in severe injury. Documented manifestations include pain, burning, redness, swelling, and ulceration. In the ocular system, symptoms may include photophobia and blurred vision. The most serious officially documented outcomes are the potential for severe irreversible anterior eye injury and blindness.

When to Seek Immediate Help

Should accidental contact with the eyes or mucous membranes occur, the official regulatory guidance mandates immediate irrigation for at least 15 minutes using copious amounts of water, normal saline, or an eyewash solution. Following irrigation, immediate medical consultation must be obtained, and an ophthalmologic consultation is required for eye exposure. If the gel is accidentally swallowed (ingested), contact with a Poison Control Center is required. Emergency services must be called if signs of acute systemic distress, such as collapse or trouble breathing, are present. No specific antidote is documented in the official regulatory labeling.

Therapeutic Uses of Valchlor

What Valchlor Treats: Main Uses and Benefits

Valchlor is relevant for managing specific cancer manifestations that primarily affect the skin.

Management of Cutaneous T-cell Lymphoma Manifestations

Valchlor is an agent used in managing Mycosis Fungoides (MF), a specific form of Cutaneous T-cell Lymphoma (CTCL), relevant for the disease when its manifestations are generally limited to the skin. This application supports symptomatic relief in the affected area. It is applicable within clinical settings that involve acute or disruptive symptom patterns and is relevant in contexts marked by increased discomfort or tension.

Addressing Visible Lesions and Symptom Clusters

The medication is applied to manage visible symptoms that interfere with daily functioning, such as the patches (flat, discolored areas) and plaques (raised, thickened lesions) on the skin. This supports easing the burden of these abnormal skin lesions. This contributes to easing the overall symptom load by addressing symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.

Role in Localized and Ongoing Symptom Support

This medication is relevant as a form of localized skin management, often employed when patients have already received other local therapies. It is applied across domains where additional symptomatic support is needed and is relevant in situations involving recurrent or episodic manifestations. It is commonly used to support long-term disease management, assisting with supporting general patient stability and contributing to the sustained management of the condition's skin manifestations.


Quick Fact: Support for Cutaneous Lesions

Valchlor is relevant for managing conditions presenting with patches and plaques and is commonly used in contexts where supportive management of symptoms is needed for adult patients with Cutaneous T-cell Lymphoma.

Eligibility and Restrictions for Use

Eligibility for Valchlor: Official Regulatory Status

Valchlor (chlormethamine topical gel) is strictly limited to use in adults who have been diagnosed with Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), typically following prior skin-directed therapies. Its safety and effectiveness have not been established in children (pediatric patients).


Eligibility scope Regulatory Statement
Populations Contraindicated Patients with a known severe hypersensitivity to mechlorethamine must not use the medicine.
Pregnancy Eligibility Use is not recommended; the medicine may cause fetal harm, and women must avoid becoming pregnant during treatment.
Lactation Eligibility Breastfeeding mothers should not breastfeed due to the potential for serious adverse reactions in the infant.
Eligibility-Related Restrictions Treatment must be stopped if a patient develops severe cutaneous reactions, such as skin ulceration, blistering, or moderately-severe or severe dermatitis. Males and females of reproductive potential are required to use a barrier method of contraception during therapy.

What should I know about interactions with other medicines?

The official interaction profile for Valchlor (mechlorethamine topical gel) is defined by constraints related to its formulation and local application rather than systemic drug-drug interactions. Use of the gel is formally contraindicated in patients with a known severe hypersensitivity to the active ingredient, mechlorethamine.

Pharmacokinetic and Metabolic Risk

Regulatory pharmacokinetic studies found that mechlorethamine was undetectable in plasma (below 0.5 ng/mL) following topical administration. This finding establishes a minimal risk for conventional systemic drug-drug interactions, including those mediated by Cytochrome P450 enzymes or drug transporters.

Procedural and Environmental Restrictions

Product Category/Substance Official Regulatory Requirement
Emollients (Moisturizers) A 2-hour separation is mandatory for application; emollients must be applied 2 hours before or 2 hours after the gel.
Alcohol / Flammability Valchlor is an alcohol-based gel and is flammable. Patients must avoid fire, flame, and smoking until the applied gel has completely dried on the skin.

Mechanism of Action

Irreversible DNA Damage via Alkylation

Valchlor’s active ingredient, chlormethine, is a bifunctional alkylating agent that acts as a localized cytotoxic agent. The molecule rapidly converts into a highly reactive aziridinium ion intermediate, which performs an electrophilic attack on the DNA's guanine bases. This molecular interaction creates permanent, structurally catastrophic DNA cross-links that physically obstruct the fundamental processes of DNA replication and transcription within the cell.


Cytotoxic Cascade and Cell Cycle Arrest

This irreparable genetic damage triggers the cell’s internal DNA damage checkpoints, forcing the highly proliferative cell into an immediate halt. This mitotic arrest predominantly occurs at the G2/M phase, which is the step leading to the inhibition of proliferation in cells with high mitotic rates. This failure to repair the damage ultimately channels the injured cells toward apoptosis.


Localized Induction of Programmed Cell Death (Apoptosis)

Apoptosis is the genetically regulated cellular self-destruction that results from the unfixable DNA injury. The physiological consequence of this localized cytotoxic mechanism is the removal of highly proliferative cells within the area of application through programmed cell death. This continuous clearance is the result of the drug's mechanism targeting cells with elevated mitotic activity.

Dosage and Administration Information

How Valchlor is Used: Official Administration Guidelines

Valchlor (mechlorethamine gel) is a highly regulated, prescription-only medication. Its use is defined by official prescribing protocols to ensure appropriate administration.


Application Method and Frequency

Administration Scope Official Instruction
Route of Administration Topical (Dermal) application only.
Standard Dosing Apply a thin film of the gel to the affected skin areas.
Frequency Once daily application.
Target Population Indicated for adult patients

Key Procedural Steps and Constraints

The application process requires adherence to specific conditions for proper use:

  • Preparation: The person applying the gel must wear disposable nitrile gloves to prevent accidental exposure to the cytotoxic drug.
  • Skin Condition: The gel must be applied only to completely dry skin.
  • Washing/Bathing: Application must occur at least 4 hours before or 30 minutes after showering or washing the treated area.
  • Drying Time: Allow the gel to dry on the skin for 5 to 10 minutes before covering the area with clothing.
  • Other Products: Emollients may only be applied 2 hours before or 2 hours after the application of Valchlor.
  • Restrictions: Do not use occlusive dressings on treated areas. The gel is flammable; avoid open flames and smoking until the gel is completely dry.

Dose Modification Protocol

Official instructions include a protocol for temporary frequency reduction if the patient experiences local skin reactions such as severe dermatitis, blistering, or ulceration. Treatment is interrupted until the skin reaction improves, then may be re-initiated at a reduced frequency (e.g., once every three days) before gradually attempting to return to the once-daily schedule.

Recent Clinical Evidence

Valchlor: Recent Clinical Evidence


Evidence for Mycosis Fungoides-Type CTCL Stage IA and IB

The research base for Valchlor (chlormethamine gel) was studied for use in early stages of Mycosis Fungoides (MF), which is a type of Cutaneous T-cell Lymphoma (CTCL), particularly Stage IA and IB. The primary evaluation involved a large-scale, randomized, controlled study, a type of research often used as a foundation for clinical evidence.

Research examined patients who had received previous skin-directed therapy, monitoring outcomes related to physical discomfort and inflammatory states using specific assessment tools like the CAILS score. The pivotal study was evaluated in a non-inferiority comparison, meaning research examined whether the gel performed similarly to an established compounded ointment. Findings describe patterns that met the pre-specified criteria for non-inferiority relative to that active comparator.


Long-Term Studies and Population Coverage

Research has explored both short-term symptom changes and longer observation periods. The primary assessment in the controlled trials had a follow-up duration of up to 12 months. For data extending beyond one year, evidence quality varies across studies; lower-tier observational studies have monitored patients for a longer duration, up to two years.

Studies primarily monitored adults with early-stage disease. However, data for certain groups remain insufficient. For instance, patients in the pivotal study were excluded if they were using common treatments such as topical corticosteroids, meaning subgroup findings are uncertain for those using this combination.


Research Gaps and Uncertainty

It is important to understand where the available research remains limited. One key limitation is that comparative evidence is insufficient between the gel and a neutral, non-active control (placebo), as the main trial was structured to compare the gel to an existing active drug.

Furthermore, the results apply only to the populations studied, meaning the core evidence does not fully characterize the experience of patients with more extensive or later-stage disease. There is also limited information for long-term outcomes that is derived from high-quality controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Valchlor (FAQ)


Q: What are the long-term risks associated with using Valchlor gel?

Official regulatory documents include a warning that there is an increased risk of developing Non-Melanoma Skin Cancer (NMSC) during and after using Valchlor. This safety consideration stems from the drug's mechanism as an alkylating agent, and it is a known potential risk that is communicated in the official prescribing information.


Q: Does applying Valchlor cause any noticeable burning or stinging sensation?

The most common side effects observed in studies are skin reactions localized to the application site, such as dermatitis, redness, swelling, and itching. Burning or stinging sensations are specifically noted in the official information as a possible symptom if the gel accidentally gets into sensitive areas like the eyes, mouth, or nose. The official guidelines provide a protocol for treatment interruption should severe skin reactions occur.


Q: Can I go swimming or exercise after applying Valchlor?

Official instructions state that the application area should remain dry for a period of time. The instructions advise waiting at least 4 hours after applying Valchlor before engaging in activities like bathing, showering, or swimming. This time frame allows the gel to be absorbed locally before the skin is washed.


Q: If Valchlor is stored in the refrigerator, how long can it be left at room temperature before it spoils?

The medication is required to be kept refrigerated between 2 C and 8 C for stability. Official patient labeling notes that healthcare providers or pharmacists should be consulted if the gel has been left out of the refrigerator for more than one hour in a single day. This precaution is important to help maintain the drug's effectiveness.


Q: Can I use other prescription topical medications with Valchlor?

Official guidance is provided for emollients (moisturizers), which must be applied 2 hours before or 2 hours after the gel. Furthermore, research documentation indicates that patients using topical corticosteroids were excluded from the pivotal clinical trials, meaning the safety and effectiveness of that specific combination is uncertain based on the core evidence. Guidance on the appropriate use of multiple prescribed topical treatments should be obtained from a healthcare provider.


Q: Does Valchlor affect my immune system or blood cell counts?

Studies found that the active ingredient, mechlorethamine, was undetectable in the bloodstream (plasma) after topical application. This suggests the medication acts locally on the skin and has minimal systemic exposure. Systemically administered mechlorethamine can affect blood cells, but this localized application limits that possibility.


Q: What happens if Valchlor accidentally gets on healthy skin?

Official labeling warns that accidental direct skin contact by the patient's caregiver or others carries a risk of developing skin irritation (dermatitis) and secondary exposure. Official procedures include washing hands immediately after handling or applying the gel to prevent unnecessary exposure.


Q: Are there any known issues with using Valchlor on the scalp or face?

Official safety information notes that the risk for severe skin problems, such as severe dermatitis or blistering, is observed to be higher if the gel is applied to sensitive areas. These sensitive areas include the face, genital area, anus, and skin folds.


Q: What should I do if I accidentally miss an application of the gel?

Official instructions indicate that if a missed application is realized, it may be applied as soon as the patient remembers. However, if the time is close to the next regular dose, the missed dose should be skipped entirely, returning to the normal schedule. It is advised not to apply two doses at the same time.


Q: Are there any specific cleaning procedures for clothes or bedding that touch the treated area?

Regulatory safety information indicates that contaminated clothing should be removed right away. The skin that came into contact with the item is advised to be flushed with water for at least 15 minutes, and the clothing requires laundering prior to being worn again.


Q: What should I do if I get Valchlor in my eyes or mouth?

Accidental contact with the eyes, mouth, or nose is considered a serious event due to the potential for severe, irreversible injury. Regulatory documents describe the procedure for accidental contact: the affected area requires immediate rinsing for at least 15 minutes with a large amount of water, saline solution, or an eyewash solution. Following this emergency rinsing, immediate medical help should be sought.


Q: Is there a maximum amount of skin area that can be treated per application?

The official regulatory instructions specify that the gel should be applied as a thin film to the affected areas of the skin. The prescribing information does not define a limit based on the percentage of body surface area for the application.


Q: Can I use cosmetic products or makeup on the treated skin areas?

Official patient labeling advises against using coverings on the treated areas. This restriction includes bandages, dressings, and makeup. Consultation with a healthcare provider is suggested if there is an intention to use coverings like makeup.


Q: Are there any known issues with driving or operating machinery while using Valchlor?

Since the medication is applied topically and absorption into the bloodstream is undetectable, the known side effects are primarily localized to the skin. This finding suggests that systemic effects, such as sedation or cognitive changes that would impair driving or operating machinery, are not expected.


Q: Does the medicine need to be washed off after a certain period of time?

The official patient labeling indicates that the medication does not need to be washed off after application. The instructions indicate that showering or washing the treated area should be avoided for at least 4 hours after the application has been completed.

How should Valchlor be stored and disposed of?

Storage and Handling Requirements for Valchlor Gel

Valchlor gel must be stored under refrigerated conditions between 2 C and 8 C (36 F and 46 F), kept away from food within the refrigerator. The product must be returned to the original carton immediately after each use. Due to its alcohol-based formulation, the gel is flammable; patients must avoid fire, flame, and smoking until the product has completely dried on the skin.

Stability and Child Safety

The gel has a limited 90-day shelf-life after dispensing and must be safely discarded if unused within that period. Application must occur immediately or within 30 minutes of removing the gel from the refrigerator. Valchlor must be stored out of the reach of children and pets.

Disposal Instructions

All unused Valchlor, empty tubes, and used disposable nitrile gloves should be safely disposed of in the household trash. Specific handling procedures for this cytotoxic drug are followed by placing all materials into the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valchlor found in:

A-Z Index: